{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Progression of Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"groups":[{"description":"The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks)\n\nsunitinib malate","id":"OG000","title":"Sunitinib Malate"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Confirmed Objective Response Rate (Complete and Partial Response) as Measured by RECIST Criteria After 2 Courses of Treatment","type":"PRIMARY","unitOfMeasure":"participants"}